



Cyclacel Pharmaceuticals, Inc.  
Investor Relations Department  
200 Connell Drive, Suite 1500  
Berkeley Heights, NJ 07922  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

**NASDAQ: CYCC <sup>1</sup>**

Last Trade:	4.12
Trade Time:	3:59 PM ET Jun 23, 2017
Change:	-0.13  (3.059%)
Day Range	4.11 - 4.44
52-Week Range	3.05 - 10.90
Volume	48,360
Market Cap. (\$M)	18.293
Shares Out (M)	4.440

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

We are a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

May 11, 2017

[Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results](#)

May 5, 2017

[Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results](#)

Apr 4, 2017

[Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140](#)

Apr 2, 2017

[Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways](#)

Mar 28, 2017

[Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

Mar 31, 2017

[Annual Report \(10-K\)](#)

Apr 12, 2017

[Definitive Proxy Statement](#)

May 12, 2017

[Quarterly Report \(10-Q\)](#)

Nov 14, 2016

[Quarterly Report \(10-Q\)](#)

Aug 11, 2016

[Quarterly Report \(10-Q\)](#)